Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New injection could cut opioid use after bunion surgery

NCT ID NCT07222748

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new medicine called TLC590 for pain after bunionectomy (foot bone surgery). About 300 adults will receive either TLC590, a standard painkiller, or a placebo. The goal is to see if TLC590 reduces pain and the need for opioid painkillers in the first 72 hours after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

304 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able and willing to provide written informed consent. 2. Male or female aged 18 years or older (inclusive). 3. Scheduled to undergo a primary unilateral, transpositional first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia. 4. ASA Physical Status Classification of 1 or 2. 5. Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence. 6. Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, or committing to the use of a highly effective method of birth control. 7. BMI \>18 \~ ≤39 kg/m2, with a minimum weight of 50 kg. Exclusion Criteria: 1. An abnormal clinical laboratory test value. 2. Evidence of a clinically significant abnormal 12-lead ECG. 3. History of orthostatic hypotension, syncope, or other syncopal attacks. 4. History or any clinical manifestation of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other conditions that have been assessed by the Investigator to make the subject unsuitable for participation in the study. 5. History of seizures or taking anticonvulsants. 6. History of cardiac arrhythmia or taking Class III antiarrhythmic drugs. 7. History of sleep apnea or at-home CPAP treatment. 8. History of hypersensitivity to ropivacaine, bupivacaine, any other amide-type local anesthetic, or any other trial-required medications. 9. History of severe or refractory PONV due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer, deemed clinically significant by the Investigator. 10. Any lifetime history of a suicidal attempt or any suicidal behavior. 11. History or positive test results of HIV, HCV, or HBV. 12. History or current report of substance abuse including illicit drug abuse and/or alcohol abuse. 13. Positive results on the urine drug screen or alcohol breath test. 14. Pre-existing concurrent acute, or chronic painful restrictive/physical condition that may confound postoperative pain assessments or is expected to require analgesic treatment during the study. 15. Has known or suspected daily use of opioids for longer than 4 days per week within 6 months. 16. Use of daily analgesics for longer than 4 days per week for a chronically painful condition. 17. Is receiving oxygen therapy. 18. Use of any of the pre-specified medications prior to the study surgical procedure or as specified. 19. Malignancy in the past 2 years, except for non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix. 20. Personal or family history of malignant hyperthermia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bunion Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Pharmacology of Miami

    Miami, Florida, 33172, United States

  • Endeavor Clinical Trials

    San Antonio, Texas, 78240, United States

  • First Surgical Hospital

    Bellaire, Texas, 77401, United States

  • Memorial Hermann Village

    Houston, Texas, 77043, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.